<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00378898</url>
  </required_header>
  <id_info>
    <org_study_id>060724</org_study_id>
    <nct_id>NCT00378898</nct_id>
  </id_info>
  <brief_title>Feasibility of Placing Bravo PH Capsule in Proximal Esophagus</brief_title>
  <acronym>bravo</acronym>
  <official_title>DUAL BRAVO PH MONITORING: A Feasibility Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessing the feasibility and patient tolerance to placement of Bravo PH capsule in proximal
      esophagus.

      There will be no difference in patient-perception of a proximally-placed Bravo esophageal pH
      monitor compared with a distal monitor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      24-hour pH monitoring is often considered the &quot;gold standard&quot; in the diagnosis of GERD and is
      increasingly utilized in patients with extra-esophageal symptoms (1). However, the clinical
      utility of pH monitoring in this patient population remains controversial. An important
      limitation of traditional pH catheters is their suboptimal sensitivity especially in patients
      with extraesophageal GERD. Vaezi et al. tested reproducibility and reliability of the
      proximal and distal esophageal pH probe in 32 patients (2). Among these patients,11 were
      controls, 10 had distal reflux, and 11 had both proximal and distal reflux. In this group of
      patients the sensitivity of distal and proximal pH probes were 70% and 55%, respectively.
      Additionally, a more recent study by Shaker et al. showed the number and duration of
      hypopharyngeal reflux events to be similar between the control subjects and patients with
      reflux laryngitis and vasomotor rhinitis (3).

      Poor sensitivity of catheter based pH monitoring in detecting acid reflux may be due to day
      to day variability of test, its less than adequate reliability as well as possible
      intermittent nature of the reflux events (not recorded in only a 24-hour period) (4).
      Additionally, since the traditional ambulatory device is commonly placed transnasally through
      the oropharynx into the esophagus, patients often complain of throat and nose discomfort and
      usually restrict their daily activity. This potentially leads to false negative findings and
      reduced test sensitivity. Furthermore, incorrect results may be collected if the pH electrode
      slips away from the initial manometrically determined placement site. In light of these
      limitations, a new wireless (catheter free) pH monitoring device was developed to improve
      patient comfort and increase test sensitivity. The Bravo pH monitoring system (Medtronic Inc,
      Minneapolis, MN) uses a radiotelemetric capsule temporarily attached to the esophageal mucosa
      which transmits pH data to a receiver carried on patient's belt.

      Although well studied in the distal esophagus, there are currently no studies in adults
      assessing the feasibility and patient tolerance to placement of this device more proximally.
      Such a placement may increase the sensitivity of the test and add to our ability to study
      potential predictors of treatment response in patients with extraesophageal GERD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients Requiring Endoscopic Removal of BRAVO Because of Reported Discomfort</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects Reporting Chest Pain</measure>
    <time_frame>48 hours</time_frame>
    <description>Edmonton Symptom Assessment is used to measure the presence and change in symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>EGD with proximal BRAVO capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects have a second BRAVO capsule placed 10cm proximal to prior BRAVO capsule placement. Fluoroscopy is used to confirm detachment of the monitor 7 days after investigational deployment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EGD with sham BRAVO capsule placement</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Subjects have a EGD with BRAVO delivery introducer positioned 10cm proximal to prior BRAVO capsule placement with no BRAVO placed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BRAVO capsule</intervention_name>
    <arm_group_label>EGD with proximal BRAVO capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fluoroscopy</intervention_name>
    <description>one time &quot;xray&quot; to determine evacuation of bravo</description>
    <arm_group_label>EGD with proximal BRAVO capsule</arm_group_label>
    <other_name>one time &quot;xray&quot; to determine evacuation of bravo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sham BRAVO capsule placement</intervention_name>
    <arm_group_label>EGD with sham BRAVO capsule placement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion criteria will include the following:

          -  Patients greater than or equal to 18 years of age

          -  Patients having regularly scheduled upper endoscopy with planned Bravo pH monitor
             testing

          -  Patients with known GERD based on symptoms (heartburn, regurgitation) and response to
             a proton pump inhibitor or esophagitis on EGD as well as those with extraesophageal
             GERD (cough, asthma and throat discomfort).

        Exclusion Criteria:

          -  Exclusion criteria will include the following:

          -  Previous surgical procedures to the upper esophagus

          -  History of bleeding diathesis or coagulopathy

          -  Stroke or transient ischemic attack within the past 6 months

          -  GI bleeding within the previous 6 months

          -  Known esophageal varices

          -  Significant medical illness (i.e., congestive heart failure)

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael F Vaezi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Vanderbilt Clinic/ Endoscopy Lab</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-5280</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2006</study_first_submitted>
  <study_first_submitted_qc>September 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2006</study_first_posted>
  <results_first_submitted>February 26, 2015</results_first_submitted>
  <results_first_submitted_qc>March 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 4, 2017</results_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Michael Vaezi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were 18 years of age or older and scheduled for esophagogastroduodenoscopy (EGD) and wireless pH testing for physiologic assessment of esophageal acid exposure for typical gastroesophageal reflux disease (GERD) symptoms such as heartburn and regurgitation or for extra-esophageal reflux symptoms such as cough or asthma at Vanderbilt.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>EGD With BRAVO Capsule</title>
          <description>Bravo PH capsule:egd with bravo placement
Fluoroscopy: one time &quot;xray&quot; to determine evacuation of bravo</description>
        </group>
        <group group_id="P2">
          <title>EGD With Sham BRAVO Capsule Placement</title>
          <description>Subjects have a EGD with BRAVO delivery introducer positioned 10cm proximal to prior BRAVO capsule placement with no BRAVO placed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis is based on participants that completed the study</population>
      <group_list>
        <group group_id="B1">
          <title>EGD With BRAVO Capsule</title>
          <description>Bravo PH capsule: egd with bravo placement
Fluoroscopy: one time &quot;xray&quot; to determine evacuation of bravo</description>
        </group>
        <group group_id="B2">
          <title>EGD With Sham BRAVO Capsule Placement</title>
          <description>Subjects have a EGD with BRAVO delivery introducer positioned 10cm proximal to prior BRAVO capsule placement with no BRAVO placed.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" lower_limit="30" upper_limit="77"/>
                    <measurement group_id="B2" value="50" lower_limit="19" upper_limit="66"/>
                    <measurement group_id="B3" value="51" lower_limit="19" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <description>based on participants that completed the study</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>based on participants that completed the study</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patients Requiring Endoscopic Removal of BRAVO Because of Reported Discomfort</title>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EGD With BRAVO Capsule</title>
            <description>Bravo PH capsule: egd with bravo placement
Fluoroscopy: one time &quot;xray&quot; to determine evacuation of bravo</description>
          </group>
          <group group_id="O2">
            <title>Sham Comparator: EGD With Sham BRAVO Capsule Placement</title>
            <description>Subjects have a EGD with BRAVO delivery introducer positioned 10cm proximal to prior BRAVO capsule placement with no BRAVO placed.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Requiring Endoscopic Removal of BRAVO Because of Reported Discomfort</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Reporting Chest Pain</title>
        <description>Edmonton Symptom Assessment is used to measure the presence and change in symptoms.</description>
        <time_frame>48 hours</time_frame>
        <population>2 subjects had to have the BRAVO removed before 48 hours due to reported discomfort in the BRAVO placement group so chest pain scores were obtained for 9 of the 11 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>EGD With Proximal BRAVO Capsule</title>
            <description>Subjects have a second BRAVO capsule placed 10cm proximal to prior BRAVO capsule placement. Fluoroscopy is used to confirm detachment of the monitor 7 days after investigational deployment.
BRAVO capsule
Fluoroscopy: one time &quot;xray&quot; to determine evacuation of bravo</description>
          </group>
          <group group_id="O2">
            <title>EGD With Sham BRAVO Capsule Placement</title>
            <description>Subjects have a EGD with BRAVO delivery introducer positioned 10cm proximal to prior BRAVO capsule placement with no BRAVO placed.
sham BRAVO capsule placement</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Reporting Chest Pain</title>
          <description>Edmonton Symptom Assessment is used to measure the presence and change in symptoms.</description>
          <population>2 subjects had to have the BRAVO removed before 48 hours due to reported discomfort in the BRAVO placement group so chest pain scores were obtained for 9 of the 11 subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.047</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients underwent baseline EGD and 48-hour wireless pH monitoring. Assessment of symptoms and any adverse events were completed 48 hours after the study intervention.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>EGD With BRAVO Capsule</title>
          <description>Bravo PH capsule: egd with bravo placement. Analysis is for participants who completed the study.
Fluoroscopy: one time &quot;xray&quot; to determine evacuation of bravo</description>
        </group>
        <group group_id="E2">
          <title>EGS With Sham BRAVO Capsule Placement</title>
          <description>Subjects have a EGD with BRAVO delivery introducer positioned 10cm proximal to prior BRAVO capsule placement with no BRAVO placed. Analysis is for participants who completed the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>Increase in baseline symptom score specific to chest pain when compared to visit 3 (48-hr post intervention)</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Selection bias may have been a limitation, as patients volunteering may have had worse symptoms and potentially altered esophageal sensitivity as compared to those who opted not to participate.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Michael Vaezi</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>615-322-3739</phone>
      <email>michael.vaezi@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

